A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
Open accessThe DOI matches its Crossref record; 327 of the 327 references it cites were found in a registry or an index; 135 of the 655 sources its claims cite were checked for support.
Abstract
Type 2 diabetes (T2D), which has currently become a global pandemic, is a metabolic disease largely characterised by impaired insulin secretion and action. Significant progress has been made in understanding T2D aetiology and pathogenesis, which is discussed in this review. Extrapancreatic pathology is also summarised, which demonstrates the highly multifactorial nature of T2D. Glucagon-like peptide (GLP)-1 is an incretin hormone responsible for augmenting insulin secretion from pancreatic beta-cells during the postprandial period. Given that native GLP-1 has a very short half-life, GLP-1 mimetics with a much longer half-life have been developed, which are currently an effective treatment option for T2D by enhancing insulin secretion in patients. Interestingly, there is continual emerging evidence that these therapies alleviate some of the post-diagnosis complications of T2D. Additionally, these therapies have been shown to induce weight loss in patients, suggesting they could be an alternative to bariatric surgery, a procedure associated with numerous complications. Current GLP-1-based therapies all act as orthosteric agonists for the GLP-1 receptor (GLP-1R). Interestingly, it has emerged that GLP-1R also has allosteric binding sites and agonists have been developed for these sites to test their therapeutic potential. Recent studies have also demonstrated the potential of bi- and tri-agonists, which target multiple hormonal receptors including GLP-1R, to more effectively treat T2D. Improved understanding of T2D aetiology/pathogenesis, coupled with the further elucidation of both GLP-1 activity/targets and GLP-1R mechanisms of activation via different agonists, will likely provide better insight into the therapeutic potential of GLP-1-based therapies to treat T2D.
Overview
CoChat Summary
TL;DR
This narrative review summarizes type 2 diabetes epidemiology, multifactorial aetiology/pathogenesis, extrapancreatic complications, and treatments, with emphasis on GLP-1 receptor-based therapies. It argues that GLP-1R agonists, including emerging allosteric and multi-receptor agonists, may improve glycaemia, weight, and systemic complications, while many mechanistic uncertainties remain.
Key findings
- T2D is described as a global pandemic: ~382 million patients globally in 2013, projected >590 million by 2035 and >700 million by 2045; T2D accounts for ~90% of diabetes cases. Obesity is a major risk factor, reported to increase T2D risk by 90-fold, and genetic susceptibility is supported by ~70% monozygotic twin concordance, 40% lifetime risk with one affected parent, and almost 70% with both parents affected.
- Pathogenesis involves beta-cell dysfunction/apoptosis, peripheral insulin resistance, alpha-cell dysregulation, islet amyloid/IAPP deposition, and a diminished incretin effect, where GLP-1 and GIP account for <20% of insulin release after glucose ingestion in T2D. Extrapancreatic pathology includes cardiovascular disease, diabetic nephropathy, neuropathy, and NAFLD, reported in ~70% of T2D patients.
- GLP-1-based therapies are central: native GLP-1 has a half-life of 1–2 minutes, whereas exenatide has 3.4–4 hours and liraglutide 11–13 hours; GLP-1R agonists augment glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and induce weight loss. In a 160-week liraglutide trial, T2D diagnosis occurred in 2% vs 6% of placebo-treated participants, and time to T2D onset was 2.7x longer with liraglutide.
- Emerging approaches include GLP-1R allosteric agonists (compounds 2 and B) and GLP-1/GIP/glucagon tri-agonists tested in rodents, which improved glycaemia, body weight, and islet architecture. Bariatric surgery can induce T2D remission—one study reported 53% complete remission at three years and another 10% partial remission—but carries complications such as vomiting/dumping syndrome, iron and B12 deficiency, and secondary hyperparathyroidism.
Methods
- Narrative review of published literature on T2D epidemiology, aetiology, pathogenesis, treatments, and future perspectives; no primary data collection or systematic search strategy is described.
- Synthesizes preclinical and clinical evidence, including rodent models, human islets, autopsy studies, and clinical trials; the main analysis is qualitative narrative synthesis.
Limitations
- The paper does not present a formal limitations section; limitations stated in the text include unresolved mechanisms, conflicting findings (e.g., glucolipotoxicity, UCP2, GIP action), uncertainty from undiagnosed diabetes in global prevalence estimates, and the caveat that animal-study observations may have limited clinical implications for humans.
- Evident from the text: as a narrative review, it lacks a described systematic search, inclusion criteria, or formal quality appraisal, and it relies on heterogeneous cited studies without meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
87 Valid · 11 Not valid · 355 Not checked · 7 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“One study demonstrated the importance of genetics in T2D susceptibility independently of the diet as there was a higher prevalence of the disease in the twin population compared to the singleton population77”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Aetiology
What the sources say
- Disputedcites [77] Poulsen, 2009, Diabetes sourceExperimental — accuracy not yet measured
The Discussion confirms that elderly twins had a higher prevalence of type 2 diabetes than singletons. But the Abstract’s Conclusions interpret the finding as evidence for a significant impact of the fetal environment “as opposed to genetics,” contrary to the claim that the comparison demonstrates the importance of genetics. These passages also do not establish independence from diet. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“It has been shown that a high proton motive force (PMF) results in the production of ROS, and as UCP2 activity can lower the PMF by increasing proton leak, it can then lower intracellular ROS, as well as increased production of ROS, is thought to be at least partly dependent on an increased mitochondrial PMF in islet beta-cells.180,183–185”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
What the sources say
- Supportedcites [180] Affourtit, 2011, Free Radic Biol Med source
The Discussion (‘UCP2 function and regulation’) says UCP2 contributes to mitochondrial proton leak. The Discussion (‘GSIS regulation by UCP2’) also describes UCP2 activity as partially dissipating mitochondrial membrane potential, supporting the claimed mechanism. (LLM, conf=0.92)
- Not checked yetcites [183] Pi, 2010, Diabetes Obes Metab source
- Disputedcites [184] Robson-Doucette, 2011, Diabetes sourceExperimental — accuracy not yet measured
The paper’s Results say UCP2 does not contribute to classical proton leak in β-cells, and its Discussion says the increased ROS observed after UCP2 deletion is not caused by reduced proton leak. Although the introduction acknowledges reports of UCP2-facilitated proton leak elsewhere, the paper’s findings contradict that mechanism in the islet β-cell context of the citing sentence. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“TNFα secretion from T2D subjects was higher than healthy controls,207,208 and one in vitro study has shown that this myokine impairs beta-cell function.208”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Extrapancreatic Tissues Involvement in T2D: Aetiology/Pathogenesis and Post-Diagnosis Complications
What the sources say
- Supportedcites [207] Ciaraldi, 2016, PLoS One source
The Results/Discussion of our copy state that TNFa secretion is elevated in T2D myotubes relative to non-diabetic cells: Discussion (p. n/a) says 'Our current observation that TNFa secretion, while low, is elevated in T2D myotubes is confirmatory of our earlier results', and the Discussion also summarizes 'our results that secretion of TNFa, IL6 and MCP-1 are all elevated in T2D myotubes'. The Introduction frames the same comparison against cells from non-diabetic (ND) individuals. Note the parallel circulating TNFa difference in Table 2 was not retained after BMI adjustment, but the claim concerns secretion, which the paper supports. (LLM, conf=0.90)
- Disputedcites [208] Bouzakri, 2011, Diabetes sourceExperimental — accuracy not yet measured
Our copy contains no measurement of TNF-α secretion comparing type 2 diabetic subjects with healthy controls; the study is entirely in vitro, using human myotubes rendered insulin resistant by added TNF-α (RESULTS, 'Myokine expression and secretion from human skeletal muscle cells (myotubes) treated with or without TNF-α'). On the contrary point, the DISCUSSION states 'At present, there is little evidence for elevated TNF-α in the skeletal muscle of individuals with type 2 diabetes,' and the background passage (labeled Abstract > CONCLUSIONS in our copy) says the source of increased circulating TNF-α in type 2 diabetes 'remains unclear, but it does not appear to be the muscle itself (18),' with elevated levels in obesity/T2D credited to refs 18-19 rather than shown here. So the muscle-derived ('myokine') elevation the citing sentence attributes to this source is contradicted by our copy; only the separate in vitro β-cell/GSIS impairment finding (TNF-α in TM blunting GSIS, blocked by Ethanercept) is supported. (LLM, conf=0.68)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There are a range of effective treatments that reduce hyperglycaemia in T2D patients, which mediate their effects by improving insulin secretion or decreasing peripheral tissue insulin resistance.8”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [8] Raz, 2013, Diabetes Care source
The paper’s sections on individual drug classes describe several effective glucose-lowering treatments with these mechanisms. The sulfonylureas and meglitinides section says they increase insulin secretion, while the PPAR-γ: pioglitazone section says that class lowers blood glucose by reducing insulin resistance and improving insulin sensitivity in muscle. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Better glycaemic control has been reported in T2D patients who have lost weight, and excess body weight is associated with the risk of cardiometabolic complications, which are major causes of morbidity and mortality in T2D and obese individuals.11,12”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [11] Horton, 2010, Diabetes Care source
The Conclusions report that weight loss was associated with better glycemic control in patients with type 2 diabetes. The Results (Regression analysis) specify that this benefit appeared with any weight loss in exenatide-treated patients, but only with weight loss of at least 8% in the sitagliptin and insulin groups. (LLM, conf=0.92)
- Supportedcites [12] Wilding, 2014, Int J Clin Pract source
The ‘Effects on glycaemic control’ section says that weight loss improves glycaemic control in people with T2DM and that those who lose weight are more likely to reach target HbA1c values. The ‘Message for the clinic’ and Introduction also link excess weight to cardiometabolic complications and cardiovascular risk. Page numbers are not available in our copy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
212 more claims · 48 with their cited sources checked
Create a free account to see all 460 claims and to verify the 520 references still open.
- It may state two separate claims as one. 213
- Probably not a substantial claim. 60
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging evidence supports the concept that deposition of ectopic fat within pancreatic islets, possibly inside β cells themselves, contributes to progressive impairment of β-cell function (which is reversible with weight loss)115 in individuals who are genetically susceptible.116–118”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [116]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“peripheral insulin resistance is a requisite precursor for the development of this disease.”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“T2D has been shown to manifest in non-overweight individuals in the absence of insulin resistance, although this is thought to be rare.140”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“exenatide has a half-life of 3.4–4 hours”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“| Exenatide (Byetta) | Twice daily | 2.4 hours | Yes |”
Citations
Cites
1 retracted
Items 201–327 of 327
Altered Islet Composition and Disproportionate Loss of Large Islets in Patients with Type 2 Diabetes
Kilimnik, G., Zhao, B., Jo, J., Periwal, V., Witkowski, P., Misawa, R., & Hara, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027445 · Cited by 132
Bhansali, A. K., Upreti, V., Khandelwal, N. K., Marwaha, N., Gupta, V., Sachdeva, N. K., Sharma, R. R., Saluja, K., Dutta, P. R., Walia, R., et al. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.0164 · Cited by 132
Pancreatic β-Cell Proliferation in Obesity
Linnemann, A. K., Baan, M., & Davis, D. B. (2014) · Advances in Nutrition · doi:10.3945/an.113.005488 · Cited by 132
Brunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130
Development of life-expectancy tables for people with type 2 diabetes
Leal, J., Gray, A. M., & Clarke, P. M. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehn567 · Cited by 128
Mensink, M., Blaak, E. E., van Baak, M. A., Wagenmakers, A. J. M., & Saris, W. H. M. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2548 · Cited by 128
Kiba, T. (2004) · Pancreas · doi:10.1097/00006676-200408000-00019 · Cited by 126
Bhansali, S., Dutta, P., Kumar, V., Yadav, M. K., Jain, A., Mudaliar, S., Bhansali, S., Sharma, R. R., Jha, V., Marwaha, N., et al. (2017) · Stem Cells and Development · doi:10.1089/scd.2016.0275 · Cited by 126
Rubin, M. R., & Patsch, J. (2016) · Bone Research · doi:10.1038/boneres.2016.1 · Cited by 124
Regulation of GLUT4 and Insulin-Dependent Glucose Flux
Olson, A. L. (2012) · ISRN Molecular Biology · doi:10.5402/2012/856987 · Cited by 123
Bouzakri, K., Plomgaard, P., Berney, T., Donath, M. Y., Pedersen, B. K., & Halban, P. A. (2011) · Diabetes · doi:10.2337/db10-1178 · Cited by 122
Diabetes & coronary heart disease: Current perspectives
Ali, M. K., Narayan, K. M. V., & Tandon, N. (2010) · The Indian Journal of Medical Research · doi:10.4103/ijmr.2010_132_05_584 · Cited by 122 · cited 1×
“diabetic patients and on average individuals with T2D have an increased risk of shorter life expectancy.(44,45) There are a”
Basu, R., Barosa, C., Jones, J., Dube, S., Carter, R., Basu, A., & Rizza, R. A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3056 · Cited by 121
Hepatitis C virus infection and insulin resistance
Bose, S. K. (2014) · World J Diabetes · doi:10.4239/wjd.v5.i1.52 · Cited by 118
Kawaguchi, M., Techigawara, M., Ishihata, T., Asakura, T., Saito, F., Maehara, K., & Maruyama, Y. (1997) · Heart and Vessels · doi:10.1007/bf02766802 · Cited by 118
Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy
Paz-Filho, G., Mastronardi, C. A., Delibaşı, T., Wong, M., & Licinio, J. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000800005 · Cited by 115
GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts
Xu, G., Kaneto, H., Lopez-Avalos, M. D., Weir, G. C., & Bonner-Weir, S. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.11.007 · Cited by 115
Glucose-Dependent Granule Docking Limits Insulin Secretion and Is Decreased in Human Type 2 Diabetes
Gandasi, N. R., Yin, P., Omar-Hmeadi, M., Ottosson Laakso, E., Vikman, P., & Barg, S. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.12.017 · Cited by 115
Sreekumar, R., Unnikrishnan, J., Fu, A., Nygren, J., Short, K. R., Schimke, J., Barazzoni, R., & Nair, K. S. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00554.2001 · Cited by 114
“Deficiency” of Mitochondria in Muscle Does Not Cause Insulin Resistance
Holloszy, J. O. (2013) · Diabetes · doi:10.2337/db12-1107 · Cited by 111
Fatty acid metabolism in obesity and type 2 diabetes mellitus
Blaak, E. E. (2003) · Proceedings of The Nutrition Society · doi:10.1079/pns2003290 · Cited by 110
Autoimmune Aspects of Type 2 Diabetes Mellitus - A Mini-Review
Itariu, B. K., & Stulnig, T. M. (2014) · Gerontology · doi:10.1159/000356747 · Cited by 107
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107
Yamamoto, M., Yamaguchi, T., Nawata, K., Yamauchi, M., & Sugimoto, T. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2537 · Cited by 106
Kim, J. Y., Song, E. H., Lee, H. J., Oh, Y. K., Park, Y. S., Park, J.-W., Kim, B. J., Kim, D. J., Lee, I., Song, J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.142315 · Cited by 94
Incretin Effects on β-Cell Function, Replication, and Mass
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s230 · Cited by 92
Reactive oxygen species and uncoupling protein 2 in pancreatic β ‐cell function
Pi, J., & Collins, S. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01269.x · Cited by 91
Increased Risk of Type 2 Diabetes in Elderly Twins
Poulsen, P., Grunnet, L. G., Pilgaard, K., Storgaard, H., Alibegovic, A., Sonne, M. P., Carstensen, B., Beck-Nielsen, H., & Vaag, A. (2009) · Diabetes · doi:10.2337/db08-1714 · Cited by 91
Bariatric surgery for treatment of obesity
Eldar, S., Heneghan, H. M., Brethauer, S. A., & Schauer, P. R. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.142 · Cited by 89
Vaag, A., & Lund, S. S. (2007) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h07-100 · Cited by 89
Relationships between Mitochondrial Function and Metabolic Flexibility in Type 2 Diabetes Mellitus
van de Weijer, T., Sparks, L. M., Phielix, E., Meex, R. C., van Herpen, N. A., Hesselink, M. K. C., Schrauwen, P., & Schrauwen-Hinderling, V. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0051648 · Cited by 87
A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification
Nolte, W. M., Fortin, J.-P., Stevens, B. D., Aspnes, G. E., Griffith, D. A., Hoth, L. R., Ruggeri, R. B., Mathiowetz, A. M., Limberakis, C., Hepworth, D., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1581 · Cited by 86
Chronic complications in newly diagnosed patients with Type 2 diabetes mellitus in India
Sosale, A., KUMAR, K. M. P., SADIKOT, S. M., Nigam, A., Bajaj, S., Zargar, A. H., & Singh, S. K. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.131184 · Cited by 86
Affourtit, C., & Brand, M. D. (2008) · Biochemical Journal · doi:10.1042/bj20070954 · Cited by 85
Identification of Autoantibody-Negative Autoimmune Type 2 Diabetic Patients
Brooks-Worrell, B. M., Reichow, J. L., Goel, A., Ismail, H., & Palmer, J. P. (2011) · Diabetes Care · doi:10.2337/dc10-0579 · Cited by 83
Provenzale, D., Reinhold, R. B., Golner, B., Irwin, V, Dallal, G. E., Papathanasopoulos, N., Sahyoun, N., Samloff, I. M., & Russell, R. M. (1992) · Journal of the American College of Nutrition · doi:10.1080/07315724.1992.10718193 · Cited by 83
Affourtit, C., Jastroch, M., & Brand, M. D. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.12.020 · Cited by 83
Faerch, K., Hulman, A., & P.J. Solomon, T. (2015) · Current Diabetes Reviews · doi:10.2174/1573399811666150416122903 · Cited by 82
Glucolipotoxicity in Pancreatic β-Cells
Kim, J.-W., & Yoon, K.-H. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.5.444 · Cited by 82
Yazhen, Z., Wenyi, C., Bing, F., & Hongcui, C. (2020) · Aging and disease · doi:10.14336/ad.2019.0421 · Cited by 82
β-Cell failure in type 2 diabetes
Leibowitz, G., Kaiser, N., & Cerasi, E. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00094.x · Cited by 78
Elder, D. A., Prigeon, R. L., Wadwa, R. P., Dolan, L. M., & D’Alessio, D. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0853 · Cited by 78
On the role of uncoupling protein-2 in pancreatic beta cells
Affourtit, C., & Brand, M. D. (2008) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.03.022 · Cited by 78
Achenbach, P., Hummel, M., Thümer, L., Boerschmann, H., Höfelmann, D., & Ziegler, A. G. (2013) · Diabetologia · doi:10.1007/s00125-013-2896-y · Cited by 76
Exercise Training and Insulin Resistance: A Current Review
Keshel, T. E. (2015) · Journal of Obesity & Weight Loss Therapy · doi:10.4172/2165-7904.s5-003 · Cited by 76 · cited 1×
“resistance and reduce the risk of T2D associated postdiagnosis complications.(242,243) If this treatment regime is”
Yoshino, J., Almeda-Valdes, P., Patterson, B. W., Okunade, A. L., Imai, S.-I., Mittendorfer, B., & Klein, S. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1579 · Cited by 75
DeLany, J. P., Dubé, J. J., Standley, R. A., Distéfano, G., Goodpaster, B. H., Stefanović-Račić, M., Coen, P. M., & Toledo, F. G. S. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2512 · Cited by 74
Woerle, H. J., Carneiro, L., Derani, A., Göke, B., & Schirra, J. (2012) · Diabetes · doi:10.2337/db11-1701 · Cited by 73
Altered islet amyloid polypeptide (amylin) gene expression in rat models of diabetes
Bretherton-Watt, D., Ghatei, M. A., Bloom, S. R., Jamal, H., Ferrier, G. J. M., Girgis, S. I., & Legon, S. (1989) · Diabetologia · doi:10.1007/bf00297454 · Cited by 71
Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2035 · Cited by 71
Nervous glucose sensing regulates postnatal β cell proliferation and glucose homeostasis
Tarussio, D., Metref, S., Seyer, P., Mounien, L., Vallois, D., Magnan, C., Foretz, M., & Thorens, B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69154 · Cited by 71
Gurgul-Convey, E., Mehmeti, I., Lortz, S., & Lenzen, S. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0747-1 · Cited by 70
Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice
Tamura, K., Minami, K., Kudo, M., Iemoto, K., Takahashi, H., & Seino, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126003 · Cited by 70
β‐cell mass in people with type 2 diabetes
Cho, J., Kim, J., Shin, J., Shin, J., & Yoon, K. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00072.x · Cited by 69
Insulin Resistance Is Not Necessarily an Essential Component of Type 2 Diabetes
Gerich, J. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6646 · Cited by 68 · cited 1×
“Strikingly, T2D has been shown to manifest in non-overweight individuals in the absence of insulin resistance, although this is thought to be rare.(140) This implies that pancreatic exocrine dysfunction can induce T2D independent of both insulin resistance and a BMI>25.”
Mitochondrial involvement in skeletal muscle insulin resistance: A case of imbalanced bioenergetics
Affourtit, C. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.07.008 · Cited by 67
Oral delivery of insulin with intelligent glucose-responsive switch for blood glucose regulation
Zhou, X., Wu, H., Long, R., Wang, S., Huang, H., Xia, Y., Wang, P., Lei, Y., Cai, Y., Cai, D., et al. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00652-z · Cited by 67
Chang, S. A., Kim, H. S., Yoon, K. H., Ko, S. H., Kwon, H. S., Kim, S. R., Lee, W. C., Yoo, S. J., Son, H. S., Cha, B. Y., et al. (2004) · Metabolism · doi:10.1016/s0026-0495(03)00314-7 · Cited by 66
Mailloux, R. J., Fu, A., Robson-Doucette, C., Allister, E. M., Wheeler, M. B., Screaton, R., & Harper, M.-E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.393538 · Cited by 66
Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 Diabetes
Ciaraldi, T. P., Ryan, A. J., Mudaliar, S. R., & Henry, R. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158209 · Cited by 66
Recent advances in understanding the role of glucagon-like peptide 1
Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66
Self-citationIncretin dysfunction in type 2 diabetes: Clinical impact and future perspectives
Ahrén, B. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.03.001 · Cited by 64
Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block
Moon, J. S., & Won, K. C. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.1.1 · Cited by 61
Type 2 diabetes and obesity in adults
Whitmore, C. (2010) · British Journal of Nursing · doi:10.12968/bjon.2010.19.14.49041 · Cited by 59
Lean versus obese diabetes mellitus patients in the United States minority population
Coleman, N. J., Miernik, J., Philipson, L., & Fogelfeld, L. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.11.010 · Cited by 59
Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway
Wang, A., Li, T., An, P., Yan, W., Zheng, H., Wang, B., & Mu, Y. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169469 · Cited by 58
Højberg, P. V., Vilsbøll, T., Zander, M., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02579.x · Cited by 56
Treating diabetes and prediabetes by focusing on obesity management
Khaodhiar, L., Cummings, S., & Apovian, C. M. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0055-0 · Cited by 56
Zhou, X., Ji, L., Ran, X., Su, B., Ji, Q., Pan, C., Weng, J., Ma, C., Hao, C., Zhang, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0144179 · Cited by 56
Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients
ten Kulve, J. S., van Bloemendaal, L., Balesar, R., IJzerman, R. G., Swaab, D. F., Diamant, M., la Fleur, S. E., & Alkemade, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3291 · Cited by 54
Barlow, J., & Affourtit, C. (2013) · Biochemical Journal · doi:10.1042/bj20131002 · Cited by 53
Diabetic nephropathy: Time to withhold development and progression - A review
Sharaf El Din, U. A. A., Salem, M. M., & Abdulazim, D. O. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.04.004 · Cited by 53
Færch, K., & Vaag, A. (2011) · Acta Diabetologica · doi:10.1007/s00592-010-0245-x · Cited by 52
Okon, E. B., Chung, A. W. Y., Zhang, H., Laher, I., & van Breemen, C. (2007) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y07-026 · Cited by 50
Khoo, C. M., Leow, M. K., Sadananthan, S. A., Lim, R., Venkataraman, K., Khoo, E. Y. H., Velan, S. S., Ong, Y. T., Kambadur, R., McFarlane, C., et al. (2013) · Diabetes · doi:10.2337/db13-1483 · Cited by 50
Diabetes after Bariatric Surgery
Shah, A., & Laferrère, B. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.12.009 · Cited by 50
Bariatric surgery and diabetes remission: Who would have thought it?
Singh, A., Singh, R., & Kota, S. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.163113 · Cited by 48
Haskell, B. D., Flurkey, K., Duffy, T. M., Sargent, E. E., & Leiter, E. H. (2002) · Laboratory Investigation · doi:10.1097/01.lab.0000018915.53257.00 · Cited by 47
Rising incidence and challenges of childhood diabetes. A mini review.
Cizza, G., Brown, R. J., & Rother, K. I. (2012) · PubMed · doi:10.3275/8411 · Cited by 47
Vangipurapu, J., Stančáková, A., Kuulasmaa, T., Kuusisto, J., & Laakso, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124028 · Cited by 46
An Association of Herpes Simplex Virus Type 1 Infection With Type 2 Diabetes
Sun, Y., Pei, W., Wu, Y., & Yang, Y. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.435 · Cited by 46
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Mazzotti, A., Caletti, M. T., Marchignoli, F., Forlani, G., & Marchesini, G. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.12.028 · Cited by 46
Barlow, J., Jensen, V. H., Jastroch, M., & Affourtit, C. (2016) · Biochemical Journal · doi:10.1042/bj20151080 · Cited by 45
A Review of the Treatment of Type 2 Diabetes in Children
Onge, E. S., Miller, S. A., Motycka, C., & DeBerry, A. (2015) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-20.1.4 · Cited by 44
Forst, T., Weber, M. M., & Pfützner, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/635472 · Cited by 44
Type 2 Diabetes in Children and Young Adults: A “New Epidemic”
Kaufman, F. R. (2002) · Clinical Diabetes · doi:10.2337/diaclin.20.4.217 · Cited by 44
The evolving place of incretin-based therapies in type 2 diabetes
Gallwitz, B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1435-z · Cited by 42
Obesity and diabetes: the links and common approaches
Haslam, D. (2010) · Primary Care Diabetes · doi:10.1016/j.pcd.2010.04.002 · Cited by 42
Guardado Mendoza, R., Perego, C., Finzi, G., La Rosa, S., Capella, C., Jimenez-Ceja, L. M., Velloso, L. A., Saad, M. J. A., Sessa, F., Bertuzzi, F., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3625-5 · Cited by 41
Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes
Davidson, M. B., Schriger, D. L., Peters, A. L., & Lorber, B. (2000) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2000.08024.x · Cited by 40
Review of current and emerging therapies in type 2 diabetes mellitus.
Mazzola, N. (2012) · PubMed · Cited by 39
Irwin, N., Flatt, P. R., Patterson, S., & Green, B. D. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.11.022 · Cited by 38
Is hepatic glucose production increased in type 2 diabetes mellitus?
Beck-Nielsen, H., Hother-Nielsen, O., & Staehr, P. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0088-0 · Cited by 35
Diabetic Ketoacidosis: A Review and Update
Perilli, G., Saraceni, C., Daniels, M. N., & Ahmad, A. (2013) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-012-0001-3 · Cited by 34
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
Abdominal fat: does it predict the development of type 2 diabetes?
Gastaldelli, A. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.5.1118 · Cited by 32
Obesity Paradox in Amputation Risk Among Nonelderly Diabetic Men
Sohn, M., Budiman‐Mak, E., Oh, E. H., Park, M. S., Stuck, R. M., Stone, N. J., & Pearce, W. B. (2012) · Obesity · doi:10.1038/oby.2011.301 · Cited by 32
Mulder, H., Ahrén, B., & Sundler, F. (1996) · Diabetologia · doi:10.1007/bf00418536 · Cited by 31
Rahim, F., Arjmand, B., Shirbandi, K., Payab, M., & Larijani, B. (2018) · Non-coding RNA Investigation · doi:10.21037/sci.2018.11.01 · Cited by 30
Oral Insulin Delivery Using Poly (Styrene Co-Maleic Acid) Micelles in a Diabetic Mouse Model
Bahman, F., Taurin, S., Diab, D. E., Taha, S., Bakhiet, M., & Greish, K. F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111026 · Cited by 29
Islet amyloid and type 2 diabetes: overproduction or inadequate clearance and detoxification?
Gupta, D., & Leahy, J. L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci77506 · Cited by 27
Seasonality in the incidence of type 2 diabetes: a population-based study.
Doró, P., Benkő, R., Matúz, M., & Soós, G. (2006) · PubMed · Cited by 27
Patel, V., Joharapurkar, A., Kshirsagar, S., Sutariya, B., Patel, M., Pandey, D., Patel, H., Ranvir, R., Kadam, S., Patel, D., et al. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.01.004 · Cited by 27
Seasonality in the Incidence of Type 2 Diabetes
Doró, P., Benkő, R., Matuz, M., & Soós, G. (2006) · Diabetes Care · doi:10.2337/diacare.29.01.06.dc05-1839 · Cited by 25
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24
Early Insulin Use in Type 2 Diabetes
Chiasson, J.-L. (2009) · Diabetes Care · doi:10.2337/dc09-s321 · Cited by 24
Hepatic fat is not associated with β-cell function or postprandial free fatty acid response
Rijkelijkhuizen, J. M., Doesburg, T., Girman, C. J., Mari, A., Rhodes, T., Gastaldelli, A., Nijpels, G., & Dekker, J. M. (2009) · Metabolism · doi:10.1016/j.metabol.2008.09.013 · Cited by 24
Howard, C. F. (1984) · Advances in veterinary science and comparative medicine · doi:10.1016/b978-0-12-039228-5.50010-3 · Cited by 22
Breuer, T. G. K., Menge, B. A., Banasch, M., Uhl, W., Tannapfel, A., Schmidt, W. E., Nauck, M. A., & Meier, J. J. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0330 · Cited by 20
Nesto, R., Fain, R., Li, Y., & Shanahan, W. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1178590 · Cited by 20
Cui, J., Shang, A., Wang, W., & Chen, W. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118339 · Cited by 20
Skin manifestations in Egyptian diabetic patients: a case series study
ElFangary, M., Sanad, E., Sorour, N., & ElNemisy, N. (2013) · Egyptian Journal of Dermatology and Venerology · doi:10.4103/1110-6530.123941 · Cited by 19
GIP: An Inconsequential Incretin or Not?
Pratley, R. E. (2010) · Diabetes Care · doi:10.2337/dc10-0704 · Cited by 19
Thompson, A., Stephens, J. W., Bain, S. C., & Kanamarlapudi, V. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154229 · Cited by 19
Self-citationon behalf of the China Kadoorie Biobank Collaborative Group, Si, J., Yu, C., Guo, Y., Bian, Z., Li, X., Yang, L., Chen, Y., Sun, H., Yu, B., et al. (2017) · Diabetologia · doi:10.1007/s00125-016-4200-4 · Cited by 18
Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives
Stephens, J., & Edavalath, M. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s6358 · Cited by 17
Pramlintide: Clinical Strategies for Success
Alrefai, H. A., Latif, K. A., Hieronymus, L. B., Weakley, C. R., & Moss, R. J. (2010) · Diabetes Spectrum · doi:10.2337/diaspect.23.2.124 · Cited by 16
Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists
Reed, J., Kanamarlapudi, V., & Bain, S. (2018) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000147 · Cited by 16 · cited 27×
“Evidence is also emerging that type 2 diabetic muscle may have detrimental effects on beta-cell function via secretion of myokines into circulation: myokine profiles differ between T2D patients and controls.207 TNFα secretion from T2D subjects was higher than healthy controls,207,208 and one in vitro study has shown t…”
InfluentialSelf-citationStrain, W. D., & Griffiths, J. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.292 · Cited by 16
Inherited β-Cell Dysfunction in Lean Individuals With Type 2 Diabetes
Mathews, A. E. W., & Mathews, C. E. (2012) · Diabetes · doi:10.2337/db12-0373 · Cited by 14
Clues from Bariatric Surgery: Reversing Insulin Resistance to Heal the Heart
Khalaf, K. I., & Taegtmeyer, H. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0364-1 · Cited by 13
Pfützner, A., Hermanns, I., Ramljak, S., Demircik, F., Pfützner, A. H., Kann, P. H., & Weber, M. M. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815607862 · Cited by 12
105-LB: Evening Oral Insulin (ORMD-0801) Glycemic Effects in Uncontrolled T2DM Patients
Eldor, R., Fleming, G. A., Neutel, J., Homer, K. E., Kidron, M., & Rosenstock, J. (2020) · Diabetes · doi:10.2337/db20-105-lb · Cited by 10
Hirschberg Jensen, V., & Affourtit, C. (2015) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2015.03.008 · Cited by 9
Commentary: Sub-types of diabetes--what's new and what's not
Wild, S. H., & Byrne, C. D. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt201 · Cited by 6
Erratum: Corrigendum: Crystal structure of the GLP-1 receptor bound to a peptide agonist
Jazayeri, A., Rappas, M., Brown, A. J. H., Kean, J., Errey, J. C., Robertson, N. J., Fiez-Vandal, C., Andrews, S. P., Congreve, M., Bortolato, A., et al. (2017) · Nature · doi:10.1038/nature23311 · Cited by 4
Hepatitis C virus and insulin resistance/diabetes mellitus.
Torres, D. M., & Harrison, S. A. (2008) · PubMed · Cited by 4
Research works printed but not linked: 25
- Thompson, 2013, Clin Exp Pharmacol, 1, 3
- 2010, Clinical Problems Caused by Obesity
- 2012, The Disease Burden Associated with Overweight and Obesity
- Templeman, 2017, J Endocrinol, 2017, 58
- Hu, 2011, Role Diet Lifestyle Genes, 34, 1249
- 2011, Biochemistry
- Karalliedde, 2016, Nephrol Dialysis Transplant, 31, 206
- Ali, 2010, Indian J Med Res, 132, 584
- Mazzola, 2012, Am J Manag Care, 18, 17
- Saeedi, 2019, Diabetes Res Clin Pract, 2, 157
- 1985, Diabetes in America
- Hyttinen, 2003, Nationwide Follow Up Study, 52, 1052
- Torres, 2008, Gastroenterol Hepatol (N Y), 4, 568
- Wilcox, 2005, Clin Biochemist Rev, 26, 19
- Cnop, 2005, Many Differences Few Similarities, 54, S97
- Gerich, 2000, J Clin Endocrinol Metab, 85, 2113
- Ivan Quesada, 2008, J Endocrinol, 2, 68
- Shah, 2000, J Clin Endocrinol Metab, 85, 4053
- Clark, 1988, Diabetes Res, 9, 151
- Perry, 2016, Exerc Immunol Rev, 22, 94
- Keshel, 2015, J Obes Weight Loss Ther, 5, S5
- 2018, Encyclopedia of Signaling Molecules
- Halverson, 1986, Am Surg, 52, 594
- Avinoah, 1992, Surgery, 111, 137
- 2017, Encyclopedia of Signaling Molecules
Cited by
Definition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
Dietary Polyphenols as Natural Inhibitors of α-Amylase and α-Glucosidase
Ćorković, I., Gašo-Sokač, D., Pichler, A., Šimunović, J., & Kopjar, M. (2022) · Life · doi:10.3390/life12111692 · Cited by 208
“Various socioeconomic and cultural aspects cause overweight and obesity, which are consequently leading to increased risk for the disease’s development [1,2].”
BackgroundSingh, A., Shadangi, S., Gupta, P. K., & Rana, S. (2025) · Comprehensive Physiology · doi:10.1002/cph4.70003 · Cited by 163
Anh, N. H., Mai, Q. D., Dinh, N. X., Huy, T. Q., Tri, D. Q., Loan, L. T. N., Bui, H. V., & Le, A.-T. (2022) · RSC Advances · doi:10.1039/d1ra08311b · Cited by 100
Metadata
- Authors
- Reed, J., Bain, S., & Kanamarlapudi, V.
- Affiliations
- Swansea University (GB)
- Corresponding author
- Reed, Josh
- Bain, Stephen
- Kanamarlapudi, Venkateswarlu
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-08
- Volume
- Volume 14
- Pages
- 3567-3602
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC8369920
- OpenAlex
- W3191601669
- Cited by
- 441
- References
- 326
- Citations by year
- 2026: 73 · 2025: 109 · 2024: 107 · 2023: 98 · 2022: 51 · 2021: 2
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Directorate for Biological Sciences
- Medical Research Council (G0401232)
- Biotechnology and Biological Sciences Research Council (BB/S019588/1, BB/F017596/1, BB/C515455/2, 1095087)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, diabetes epidemiology, diabetes aetiology, diabetes pathogenesis, impaired insulin secretion, glucagon-like peptide-1, incretins, GLP-1 receptor agonists, bariatric surgery alternatives, weight loss, diabetes complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.